Artificial Pancreas Device System Market Report 2026

The artificial pancreas device system market size has grown rapidly in recent years. It will grow from $2.06 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to increasing prevalence of diabetes, early adoption of insulin pump technologies, expansion of continuous glucose monitoring usage, improvements in medical sensor accuracy, growing awareness of automated diabetes management.

The artificial pancreas device system market size is expected to see rapid growth in the next few years. It will grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing demand for fully automated glucose regulation, rising investments in digital diabetes care, expansion of remote patient monitoring, growing focus on personalized insulin therapy, increasing regulatory support for advanced diabetes devices. Major trends in the forecast period include increasing adoption of closed-loop glucose control systems, rising integration of cgm with insulin pumps, growing use of predictive algorithms for insulin delivery, expansion of wearable diabetes management devices, enhanced focus on patient-centric automation.

The rising incidence of pancreatic cancer is anticipated to drive the expansion of the artificial pancreas device system market in the coming years. Pancreatic cancer is a malignant growth that develops in the pancreas, a gland situated behind the stomach. The occurrence of pancreatic cancer is influenced by a mix of lifestyle, genetic, medical, and environmental factors, along with genetic mutations that cause hereditary pancreatitis, potentially leading to chronic inflammation of the pancreas. An artificial pancreas device system (APDS) is mainly designed to assist individuals with diabetes in managing their blood glucose levels by continuously monitoring glucose and delivering the required amount of insulin. For example, in March 2024, Cancer Australia, a government agency, reported that 4,506 new cases of pancreatic cancer were diagnosed in 2023, up from 3,751 cases recorded over the previous five years. Consequently, the increasing prevalence of pancreatic cancer is contributing to the growth of the artificial pancreas device system market.

Major companies in the artificial pancreas device system market are focusing on developing automated insulin delivery systems to improve diabetes management by continuously monitoring blood glucose levels and administering the appropriate insulin dosage. These automated insulin delivery systems are designed to mimic the function of a healthy pancreas, reducing the need for constant blood sugar checks and manual insulin injections for people with diabetes. For example, in May 2023, Beta Bionics, a US-based medical device manufacturer, received FDA 510(k) clearance for the iLet Insulin-Only Bionic Pancreas System, an automated insulin delivery device. This artificial pancreas system is designed to autonomously calculate and deliver insulin doses to manage blood glucose levels. The closed-loop system automatically adjusts insulin delivery based on glucose readings from a connected continuous glucose monitor (CGM), requiring only the user’s body weight and a meal size estimate to regulate insulin administration.

In September 2023, Abbott Laboratories, a US-based pharmaceutical company, acquired Bigfoot Biomedical for an undisclosed sum. This acquisition strengthens Abbott's presence in diabetes care by utilizing its leading Freestyle Libre portfolio of continuous glucose monitoring technology. It also supports the company's goal of creating connected solutions that make diabetes management more personalized and accurate. Bigfoot Biomedical is a US-based company that focuses on developing prototypes of automated insulin delivery systems, also known as artificial pancreas.

Major companies operating in the artificial pancreas device system market are Medtronic plc, Abbott Laboratories, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Roche Diabetes Care, Ypsomed, SOOIL Development, Beta Bionics Inc., Bigfoot Biomedical Inc., Diabeloop SA, Inreda Diabetic B.V., Defymed SAS, DreaMed Diabetes Ltd., Medtrum Technologies Inc., EOFlow Co. Ltd., Cellnovo, Pancreum Inc., Admetsys Corporation, GlucoModicum, MicroTech Medical.

North America was the largest region in the artificial pancreas device system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial pancreas device system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial pancreas device system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the artificial pancreas device system market by increasing costs of imported sensors, microprocessors, insulin pumps, batteries, and electronic control components used in closed-loop systems. Hospitals and diabetes care centers in North America and Europe are most affected due to reliance on imported medical electronics, while Asia-Pacific faces higher manufacturing input costs. These tariffs are raising device prices and slowing adoption among cost-sensitive patients. However, they are also encouraging local device assembly, regional supply chain development, and innovation in compact and cost-efficient pancreas systems.

The artificial pancreas device system market research report is one of a series of new reports that provides artificial pancreas device system market statistics, including artificial pancreas device system industry global market size, regional shares, competitors with a artificial pancreas device system market share, detailed artificial pancreas device system market segments, market trends and opportunities, and any further data you may need to thrive in the artificial pancreas device system industry. This artificial pancreas device system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial pancreas device system (APDS) is a medical technology developed to automate blood glucose management for people with diabetes. It combines continuous glucose monitoring (CGM) with an insulin pump and employs an advanced algorithm to automatically regulate insulin delivery based on real-time glucose measurements. The device is designed to replicate the glucose-controlling function of a healthy pancreas, reducing the need for manual blood glucose checks and insulin injections, while helping to keep blood glucose levels within a desired range.

The primary types of devices in the artificial pancreas device system market include threshold suspend device systems, control-to-range systems, and control-to-target systems. Threshold suspend device systems are insulin pump technologies used in diabetes management that automatically halt insulin delivery when blood glucose levels fall below a set threshold. The different treatment types comprise bi-hormonal, insulin-only, and hybrid, with various end-users such as hospitals, medical centers, and others.

The artificial pancreas device system market includes revenues earned by entities by providing services such as patient monitoring, device maintenance, data management, software updates, healthcare provider consultations, and training and support for patients and healthcare professionals. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial pancreas device system market also includes sales of insulin pumps, continuous glucose monitors, control algorithms and software applications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.